CDMO Medicine Technology Company Laviana Pharma Co., Ltd. Raised Nearly ￥100 Million in a Series B+ Round Funding Led by V-Capital

CDMO medicine technology company Laviana Pharma Co., Ltd. Raised nearly ￥100 million in a series B+ round funding led by V-Capital and followed by China Asset Management. The investment will be used on technology R&D and the building of business operation team.

Established in 2005, Laviana Pharma covers all chemistry-related aspects of process development and transformation for the innovative drug substances and products from laboratory scale to commercialized scale, including process research, process development, process optimization, pilot production and large-scale production of intermediates, API starting materials and API (active pharmaceutical ingredient) for pre-clinical, clinical trial materials and commercialized products.  It also provides customized R&D and manufacturing service for pharmaceutical companies.